Pillar
AI for chemistry and drug discovery, the deterministic tool layer.
Frontier LLMs hit 14 to 41 percent on pure chemistry tasks. With a deterministic MCP tool layer attached: 76 to 92 percent, three of the four tested models land at 85 to 92 %, the cheapest (Gemini 3.5 Flash) at 76 %. This page explains where AI for chemistry actually works today, where it doesn't, and how the Model Context Protocol (MCP) closes the gap. With data, no buzzwords.
What "AI for chemistry" actually means in 2026
The term gets used loosely. Three very different things sit inside it, and you shouldn't conflate them:
- AI agents with chemistry tools. An LLM like Claude, GPT, or Gemini calls deterministic chemistry functions through a standard interface. This is the stack that went productive in 2025/26. Details below, and on the MCP platform page.
- LLMs that "do" chemistry themselves. Asking an untooled LLM for logP, pKa, or an ICH M7 triage. Works for intuitive answers, fails reproducibly on hard numerical or categorical questions. The Klambauer Lab JKU measured this rigorously at ICLR 2026 (MolecularIQ benchmark), four frontier models land at 14-41 percent.
- Specialised models for chemistry (foundation models, fine-tuned LLMs). AlphaFold, RoseTTAFold, BioGPT, ChemLLM and similar. Strong in narrowly defined areas (protein folding, reaction prediction) but not an end-to-end research stack. Anyone deploying "AI for chemistry" combines these specialised models as tools, not as the only answer source.
The architecture that works in 2026 is LLM agent plus deterministic tool layer. The LLM understands the question and plans the steps. The tool layer computes. Both are separated. That is exactly what Anthropic specified in 2024 as the Model Context Protocol (MCP); since 2025 it has been an open industry standard.
Three problems AI alone doesn't solve in chemistry
Hallucination in the value space
The LLM makes up plausible but wrong numbers, logP 2.3 instead of 4.1, pKa "around 5" instead of 5.23. In pharma submissions, fatal.
Lack of audit trail
Non-reproducible answers are effectively non-existent under EU Annex 11 and 21 CFR Part 11. Pilots get cut from QA audits.
Inconsistency between runs
Even at temperature 0, the LLM gives different answers on repetition. The validation protocol can't be closed out.
More on the three failure modes and why "better data management" is the wrong answer: Data quality isn't the real bottleneck.
How MCP for chemistry closes the gap
The Model Context Protocol is the standardised interface between an LLM and a tool function. An MCP server for chemistry exposes functions like covatox_assess_ichm7_batch or covastab_design_study as deterministic tools with a clearly defined input/output contract. The LLM calls them, gets a reproducible answer back, and either communicates it to the user or chains it into another step.
Three consequences that matter directly for pharma, biotech and chemistry R&D teams:
- Validated tools, not LLM inference for computation. When the agent needs ADMET, a tox endpoint, or a stability prediction, it calls a deterministic function. Identical on call 1,000 as on call 1.
- Audit trail out of the box. Every tool call comes back version-pinned and time-stamped. Reproducibility is contractual, not "best effort".
- Standardised interface. Model Context Protocol has been jointly maintained by Anthropic, OpenAI and major open-source projects since 2025. Plug-and-play with Claude Desktop, Cursor, VS Code. No vendor lock-in.
Background and technical detail on the MCP platform page and the market overview "The 5 leading chemistry MCP servers for pharma R&D compared".
Foundation models vs tool layers, two roads for AI in chemistry
In 2026 the pharma AI industry has split into two clearly separated architectural camps. Anyone making a platform decision should understand the difference, because it determines which workflows are reproducible and which are not.
Camp A
Foundation models
One large model computes everything itself. From text prompt to molecular 3D structure to quantum properties to retrosynthesis, in one end-to-end stack. 2026 examples: Insilico × 01.AI "MMAI Gym" (arXiv:2603.03517), ChemLLM, AlphaFold-successor models.
Strong at: Exploration of new compound classes, materials science, generative tasks where creativity beats reproducibility.
Weak at: Audit trail, reproducibility, regulatory submissions. Same prompt, two runs, two answers.
Camp B (where CovaSyn sits)
LLM + deterministic tool layer
A frontier LLM (Claude, GPT, Gemini) plans and communicates. A separate deterministic layer (CovaSyn MCP tools, RDKit, OpenMS) computes. Connected via the Model Context Protocol.
Strong at: Validation, reproducibility, ICH M7 / Q1 workflows, GxP-aligned submissions, cost at scale.
Weak at: Pure exploration without clear tool contracts. If the answer doesn't come from an existing function, the layer returns nothing.
When which architecture
Both camps will exist in pharma in 2026. They don't exclude each other, they cover different phases of the R&D lifecycle:
- Early discovery, novel modalities: Foundation models. If you're working in white space, you need generative freedom.
- Lead optimisation, toxicology triage, stability, submissions: Tool-layer architecture. When QA and an auditor are in the loop, you need reproducibility.
- Real pipelines: Both in parallel. The foundation model proposes a candidate; the tool layer validates it.
CovaSyn is explicitly the tool-layer half. We don't compete with foundation-model providers like Insilico or DeepMind, we sit underneath, making their proposals computable in a reproducible form. More on concrete application on the MCP platform page and in the market overview "The 5 leading chemistry MCP servers".
AI chemistry tool families available at CovaSyn
130 deterministic functions, grouped into 8 families. Each callable from Claude Desktop, Cursor, VS Code or your own agent stack.
Cheminformatics (covabasic, covachem)
SMILES / InChI / MOL handling, druglikeness, fingerprints, scaffold analysis, ADMET, pKa, tautomers, the standard layer for med-chem AI workflows.
Toxicology (covatox)
ICH M7 batch assessment, Tox21 endpoints, structural alerts, CYP450, ecotoxicology. 25 functions for regulatory triage.
Mass spectrometry (covams)
Formula prediction, fragment annotation, impurity profiling, metabolite ID, retention-time prediction. AI-assisted analysis with deterministic backends.
NMR (covnmr)
1D and 2D NMR analysis, predict + assign, sudoku solver, verification, identification, the NMR co-pilot.
Stability (covastab)
ICH Q1A/Q1E Arrhenius, shelf-life estimation, OOS/OOT detection, batch variability. AI-agent-ready stability modelling.
Bio (covabio)
Antibody profiling, peptide, ADC, mRNA, oligo, siRNA, immunogenicity, developability, for biotech-branch workflows.
Folding + structure (covafold, covadock)
Protein and RNA folding, binding sites, mutation analysis, docking. Pure tool layer, not just an AlphaFold wrapper.
DoE + optimization (covadoe, covaopt)
Design of experiments with AI-agent guidance, response surface modelling, process optimisation, robust conditions, for CDMO workflows.
Validated on an independent benchmark
On MolecularIQ from the Klambauer Lab (JKU Linz), 3,540 verified chemistry tasks, accepted at ICLR 2026: four frontier LLMs with and without CovaSyn MCP attached.
| Model | Baseline | + CovaSyn MCP | Lift |
|---|---|---|---|
| Claude Haiku 4.5 | 21,2 % | 85,4 % | 4,0× |
| Claude Opus 4.7 | 40,8 % | 91,5 % | 2,3× |
| OpenAI GPT-5.5 | 22,3 % | 89,9 % | 4,0× |
| Gemini 3.5 Flash | 13,7 % | 75,7 % | 5,5× |
The lift is model-independent, it comes from the deterministic tool layer, not from the model itself. Full methodology, gaps and reproduction steps.
Real workflows running with AI chemistry today
AI for drug discovery
Agent generates compound candidates, calls covachem_adme + covatox_assess_ichm7_batch for filtering, hands top hits to the med-chem team. Time-to-hit from days to hours.
AI for stability studies
Agent designs an ICH Q1A-compliant stress scheme with covastab_design_study, projects shelf life via covastab_estimate_shelf, validates against real data. Effort: 1-2 weeks instead of 6-8.
AI for ICH M7 mutagenicity triage
Agent screens an impurity library with covatox_assess_ichm7_batch, categorises into classes 1-5, generates an audit-ready justification per compound. Cuts manual triage from 80-200 h/month to under 20 h.
AI for spectroscopy analysis
Mass-spec spectrum comes in, agent calls covams_identify + covams_fragment_annotate, returns structured identification with confidence score. NMR likewise with covnmr_identify.
Who this is built for
- Pharma R&D teams. Med-chem, ADMET, regulatory triage. If you already know ICH M7 / Q1 / Annex 11, you know our vocabulary.
- Biotech and biologics teams. Antibodies, mRNA, ADCs, oligos. Bio family with developability, immunogenicity, viscosity.
- CDMOs and contract research orgs. Time-critical quote-to-quote workflows. Time-to-quote from 5-10 days to 1-3 days.
- Pharma AI engineering teams. If you run your own Claude deployment or an agent stack and want a chemistry MCP server to plug in without building it yourself.
FAQ on AI for chemistry and drug discovery
- What's the best AI stack for chemistry in 2026?
- A frontier LLM (Claude, GPT, Gemini) with a deterministic MCP chemistry tool layer underneath. The LLM understands and plans, the MCP tools compute. We benchmarked this on MolecularIQ (ICLR 2026) against untooled LLMs: lift from 14-41 % to 76-92 % accuracy, three of the four tested models land at 85-92 %.
- What's the difference between an LLM for chemistry and an AI agent for chemistry?
- An LLM for chemistry generates text (including numbers) based on its training data, it doesn't compute, it remembers. An AI agent for chemistry uses an LLM as a language and planning layer and calls deterministic tools next to it for the actual computation. The latter is reproducible and audit-able, the former is not.
- How does AI for drug discovery differ from classic cheminformatics?
- Classic cheminformatics is a deterministic function with a clearly defined input and output (RDKit, Open Babel, OpenMS). AI for drug discovery layers an AI agent on top that orchestrates workflows, interprets data and communicates with humans. They need each other: the deterministic layer guarantees correctness, the AI agent makes the experience natural.
- Can I use Claude or GPT directly for ICH M7 triage?
- Without a tool layer: not for regulatory submissions. Frontier LLMs reach 40-60 % accuracy on ICH M7-specific questions. With a deterministic Q-SAR backend attached via MCP (e.g. CovaSyn covatox_assess_ichm7_batch), the answers are reproducible and audit-ready.
- What data residency does AI for chemistry need in EU pharma?
- For EU GDPR compliance and EU Annex 11 workflows: data residency inside the EU, ideally DACH. Self-hosted (container on your own infrastructure) is increasingly required by pharma IT security. CovaSyn offers both, DACH hosting on Hetzner Leipzig and a self-hosted container option.
- What does AI for chemistry cost in practice?
- Free tier at CovaSyn (100 credits/week) covers most evaluation workflows. Pro plan €250/month for active med-chem teams. Unlimited €750/month for high-volume CDMO quote workflows. Enterprise pricing for corporates after a discovery call.
Ready to make AI actually usable in your chemistry?
Free tier with 100 credits per week, all 130 tools, pluggable into Claude Desktop, Cursor, VS Code or your own agent stack.